Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas (NasdaqGS:ARVN) - **Focus**: Development of PROTAC degraders, with four programs currently in phase one across various disease areas [5][6] Key Programs and Developments - **Pipeline**: - **Vepdegestrant**: Positive pivotal phase trial readout for ER degrader [6] - **Bavdegalutamide**: Outlicensed to Novartis, providing a strong foundation for future growth [6] - **ARV-102**: LRRK2 degrader targeting neurodegeneration, showing promise in reducing LRRK2 levels in cerebrospinal fluid [39][40] - **ARV-806**: KRAS G12D degrader for solid tumors, with rapid enrollment in clinical trials [128] - **ARV-393**: BCL6 degrader in phase 1 studies for B-cell and T-cell lymphomas, showing early responses [142][143] - **ARV-027**: Polyglutamine repeat AR degrader for Kennedy's disease, recently started in clinical trials [145] - **ARV-6723**: HPK1 degrader planned for future clinical use [146] Competitive Advantages - **PROTAC Technology**: - Allows for iterative degradation, overcoming resistance mechanisms that traditional inhibitors face [27][28] - Offers oral bioavailability and the ability to cross the blood-brain barrier, which is advantageous for treating neurodegenerative diseases [28] - **Differentiation**: Each program is focused on demonstrating unique benefits over existing therapies, such as improved efficacy and reduced resistance [20][21] Market Position and Strategy - **Commercialization**: Arvinas is seeking a new partner for the commercialization of vepdegestrant while focusing resources on earlier pipeline assets [18][19] - **Combination Therapies**: Emphasis on developing combination strategies, particularly for oncology applications, to enhance treatment efficacy [139] Clinical Insights - **LRRK2 and Neurodegeneration**: - Targeting LRRK2 is crucial for diseases like Parkinson's and progressive supranuclear palsy, with a goal to reduce LRRK2 levels by 50% to halt disease progression [81][82] - Preclinical data supports the potential for ARV-102 to impact pathologic proteins associated with these diseases [41][42] - **KRAS G12D**: - The ARV-806 program aims to demonstrate superior efficacy compared to existing inhibitors, with a focus on overcoming compensatory upregulation seen in traditional therapies [119][120] Upcoming Milestones - **Data Releases**: Anticipated data from ongoing trials, including results from ARV-102 in Parkinson's disease patients and updates on ARV-806 [68][128] - **Phase 1b Trial**: Plans to initiate a phase 1b trial for progressive supranuclear palsy by mid-year [68] Conclusion - Arvinas is positioned as a leader in the development of PROTAC degraders, with a robust pipeline and strategic focus on differentiation and combination therapies. The company is actively pursuing partnerships and preparing for significant clinical data releases in the near future.

Core Viewpoint - Arvinas and Pfizer are collaborating to out-license the commercialization rights of vepdegestrant to a third party, aiming to maximize its commercial potential for treating advanced or metastatic breast cancer [2][3] Company Actions - The company plans to implement additional cost optimization measures expected to achieve total annual savings of over $100 million compared to FY 2024 [1][7] - A stock repurchase program has been authorized for up to $100 million, reflecting the company's confidence in its long-term growth prospects [1][8][10] - The company reaffirms its cash runway guidance through the second half of 2028, indicating sufficient funds to support ongoing clinical programs [1][11] Product Development - Vepdegestrant is under FDA review as a monotherapy for ER+/HER2- advanced or metastatic breast cancer, with a PDUFA action date set for June 5, 2026 [3][14] - The drug is being developed as a potential best-in-class therapeutic option for patients with ESR1 mutations [3][12] Strategic Review - Following the decision to out-license vepdegestrant, Arvinas conducted a strategic review of its business, reaffirming the potential of its pipeline of PROTAC degraders [4][5] - The company has three investigational PROTAC degraders currently in Phase 1 trials targeting various cancers and neurodegenerative diseases [4][15] Workforce and Cost Management - The company will reduce its workforce by an additional 15% to streamline operations, particularly in roles related to vepdegestrant commercialization [6] - Additional measures will be taken to limit expenditures on the vepdegestrant program while preparing for commercialization [5][6]

Financial Data and Key Metrics Changes - The company reported a revenue of $22.4 million for the second quarter of 2025, a decrease of $54.1 million compared to $76.5 million in the same period of 2024, primarily due to reduced revenue from the Novartis license agreement and the VetDeg collaboration with Pfizer [31][32] - Cash, cash equivalents, and marketable securities at the end of the second quarter were approximately $861.2 million, down from $1.04 billion as of December 31, 2024 [31] - General and administrative expenses decreased to $25.3 million from $31.3 million year-over-year, while research and development expenses fell to $68.6 million from $93.7 million [32] Business Line Data and Key Metrics Changes - The company is focusing on three Phase I trials in its neuro and oncology portfolio, including the recently initiated trial with the KRAS G12D degrader, ARV-806 [3][4] - Significant clinical progress was made with ARV-102, the LAR2 degrader, and ARV-393, the BCL6 degrader, with compelling preclinical data supporting their advancement [4][21] - The restructuring included a reprioritization of the research pipeline, cutting several programs while continuing investment in high-potential assets [5][28] Market Data and Key Metrics Changes - The collaboration with Pfizer for VetDeg is being reworked due to the removal of combination pivotal trials, which has led to a reassessment of the co-commercialization agreement [10][30] - The company is actively seeking a new partner for VetDeg should negotiations with Pfizer not yield favorable terms [10][30] Company Strategy and Development Direction - The company aims to advance VetDeg towards commercial launch, achieve critical data milestones from its pipeline, and allocate capital efficiently [9][35] - The long-term strategy includes focusing on differentiated PROTAC technology in both neuroscience and oncology, with an emphasis on maximizing shareholder value [11][28] - The company is conducting a CEO search process to ensure leadership continuity and strategic direction [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position and the potential of its clinical pipeline to drive future value [11][28] - The company anticipates multiple near-term milestones across its clinical development and regulatory efforts, including potential approval of a PROTAC [34][35] - Management highlighted the importance of achieving critical data milestones in the next twelve months to support the company's growth trajectory [11][35] Other Important Information - The company has extended its cash runway into 2028 following the restructuring and cost-reduction measures [28][33] - The NDA for VetDeg has been submitted, marking a significant milestone as the first PROTAC degrader to enter clinical trials and submit for approval [19][31] Q&A Session Summary Question: Can you provide more details on the expected data from ARV-102 this year? - Management indicated that they expect to present data from healthy volunteers and initial data from Parkinson's patients in upcoming conferences [40][41] Question: What are the expectations for the BCL6 program and potential combination therapies? - Management emphasized the importance of establishing a monotherapy dose before exploring combination therapies, particularly with bispecifics in DLBCL [51][52] Question: How does the company plan to handle the potential return of VetDeg rights from Pfizer? - The company is negotiating with Pfizer to rework the collaboration and is prepared to seek a new partner if necessary, aiming to minimize any gaps in commercialization [68][70] Question: What is the company's outlook on the recent Phase III trial results in breast cancer? - Management stated that the results would have little impact on their modeling and confirmed they would not pursue further development with the drug in question [77][78] Question: Can you comment on the interactions with the FDA regarding the NDA submission? - Management reported that interactions with the FDA have been smooth and timely, with no current delays affecting their submission process [94][96]